Development of new hormonal male contraception for the couple
Andrology · 2024-10 · 12 (7) · 1506-1511
DOI: 10.1111/andr.13654 ↗At a glance
Übersichtsarbeit in Andrology, published online on 2024-05-15. Written by Jeffrey M Kroopnick and 2 co-authors. Institution: Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. Major MEDLINE topics: Contraceptive Agents, Male. Cited 11 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Current options for male contraception are limited to condoms, the withdrawal method, or a vasectomy. Studies indicate that men have expressed growing interest in bearing responsibility for family planning.
Objectives
To review prior studies investigating the role of an androgen‐only or androgen with progestin regimen for hormonal male contraception and to provide an update of a promising new hormonal agent, a transdermal gel.
Discussion
Thus far, there have been six studies conducted in couples evaluating the contraceptive efficacy of an androgen‐only or androgen co‐administered with a progestin regimen for hormonal male contraception. The only ongoing study is by the National Institute of Child Health and Human Development, in collaboration with the Population Council. They have developed a novel transdermal gel containing testosterone and segesterone acetate (Nestorone), a progestin. An ongoing phase II study enrolling more than 460 couples has shown great potential with respect to the product's efficacy, safety, reversibility, and acceptability. As this agent advances in development, a rapid at‐home test for sperm concentration will provide couples with immediate feedback regarding their potential for pregnancy.
Conclusion
There is promise for the first‐of‐its‐kind hormonal male contraceptive, a transdermal gel, to achieve market approval for distribution in the United States and elsewhere. Its safety, efficacy, reversibility, and user‐control are all appealing qualities that make it readily adoptable for clinical practice.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
ORCID profiles: Jeffrey M Kroopnick
Cite
APA
Kroopnick, J. M., Lee, M. S., & Blithe, D. L. (2024). Development of new hormonal male contraception for the couple. Andrology, 12(7), 1506-1511. https://doi.org/10.1111/andr.13654
Vancouver
Kroopnick JM, Lee MS, Blithe DL. Development of new hormonal male contraception for the couple. Andrology. 2024;12(7):1506-1511. doi:10.1111/andr.13654
BibTeX
@article{Kroopnick2024,
author = {Kroopnick, Jeffrey M and Lee, Min S and Blithe, Diana L},
title = {Development of new hormonal male contraception for the couple},
journal = {Andrology},
year = {2024},
volume = {12},
number = {7},
pages = {1506--1511},
doi = {10.1111/andr.13654}
}
EUVIMED